Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264;A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Annals of Oncology

Volumn 26, Issue 9, 2015, Pages 1923-1929

  O'Neil, B H ^a   Scott, A J ^b   Ma, W W ^c   Cohen, S J ^d   Aisner, D L ^b   Menter, A R ^e   Tejani, M A ^f   Cho, J K ^g   Granfortuna, J ^h   Coveler, L ⁱ   Olowokure, O O ^j   Baranda, J C ^k   Cusnir, M ^l   Phillip, P ^m   Boles, J ⁿ   Nazemzadeh, R ^o   Rarick, M ^p   Cohen, D J ^q   Radford, J ^r   Fehrenbacher, L ^s   Bajaj, R ^t   Bathini, V ^u   Fanta, P ^v   Berlin, J ^w   McRee, A J ^x   Maguire, R ^y   Wilhelm, F ^y   Maniar, M ^y   Jimeno, A ^b   Gomes, C L ^z   Messersmith, Wells A ^b   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e KAISER PERMANENTE   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g Oncare Hawaii   (United States)

^h Department of Neonatology   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF CINCINNATI   (United States)

^k UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^l MOUNT SINAI MEDICAL CENTER   (United States)

^m KARMANOS CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^o Carolina Healthcare System   (United States)

^p Kaiser Permanante Northwest   (United States)

^q NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^r Hendersonville Hematology Oncology   (United States)

^s Kaiser Permanante   (United States)

^t Landstuhl Regional Medical Center   (United States)

^u University of Massachusetts Memorial   (United States)

^v UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^w VANDERBILT INGRAM CANCER CENTER   (United States)

^x UNIVERSITY OF NORTH CAROLINA   (United States)

^y Onconova Therapeutics Inc   (United States)

^z Oncology Consortia of Criterium Inc   (United States)

more..

Author keywords

Pancreatic cancer; Phase II III; PI3K inhibitor; PLK1 inhibitor; Ras mimetic; Rigosertib

Indexed keywords

GEMCITABINE; RIGOSERTIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CELL CYCLE PROTEIN; DEOXYCYTIDINE; GLYCINE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; POLO-LIKE KINASE 1; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; SULFONE; TP53 PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; AGED; ANEMIA; ARTICLE; ASIAN; BLACK PERSON; CAUCASIAN; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; HAZARD RATIO; HISPANIC; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPONATREMIA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENETICS; MIDDLE AGED; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); SULFONES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84941631526     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw095     Document Type: Erratum

References (22)

1. Society AC. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society 2014.
2. Li D, Xie K, Wolff R et al. Pancreatic cancer. Lancet 2004; 363(9414): 1049-1057.
3. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6): 2403-2413.
4. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15): 1960-1966.
5. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19): 1817-1825.
6. Al-Hajeili M, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. OncoTargets Ther 2014; 7: 187-192.
7. Gray PJ Jr, Bearss DJ, Han H et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004; 3(5): 641-646.
8. Jimeno A, Li J, Messersmith WA et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008; 26(34): 5504-5510.
9. Ma WW, Messersmith WA, Dy GK et al. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res 2012; 18(7): 2048-2055.
10. Divakar S, Vasqez-Del Caprio R, Baker SJ et al. Targeting the Ras-Binding domain of Ras effector proteins by a small molecule inhibitor, Rigosertib. Cancer Res 2014; 74(Suppl 19): abstr nr LB-108.
11. Van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005; 24(17): 2844-2859.
12. Jimeno A, Rubio-Viqueira B, Rajeshkumar NV et al. A fine-needle aspiratebased vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 2010; 9(2): 311-318.
13. Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs 2011; 20(4): 507-518.
14. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, N.Y.) 2008; 321 (5897): 1801-1806.
15. Eser S, Schnieke A, Schneider G et al. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 2014; 111(5): 817-822.
16. Jimeno A, Chan A, Cusatis G et al. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene 2009; 28(4): 610-618.
17. Singh A, Greninger P, Rhodes D et al. A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer cell 2009; 15(6): 489-500.
18. Collisson EA, Sadanandam A, Olson P et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17(4): 500-503.
19. Komrokji RS, Raza A, Lancet JE et al. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol 2013; 162(4): 517-524.
20. Silverman LR, Greenberg P, Raza A et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol 2014; 33(2): 57-66.
21. Raza A, Mukherjee S, Eisenberger AJ et al. A phase II study of the orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients. J Clin Oncol 31 2013; 7031.
22. Hyoda T, Tsujioka T, Nakahara T et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci 2015; 106(3): 287-293.